Anavex Life Sciences has announced promising findings from its 48-week Phase 2 extension study of
ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s disease dementia. The
data reveal that patients experienced consistent clinical improvements while on the drug. 

The study assessed multiple efficacy endpoints, including the Movement Disorder Society-Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) and Clinical Global Impression –
Improvement (CGI-I). Findings showed that patients exhibited better performance
across these metrics during the extension phase, suggesting a potential to slow
or even reverse Parkinson’s disease symptoms. 

ANAVEX®2-73, an oral small-molecule activator of the sigma-1 receptor, aims to restore neural
cell homeostasis and promote neuroplasticity. The drug has demonstrated both
safety and tolerability, consistent with its known safety profile. The study
highlighted that patients on ANAVEX®2-73 not only maintained but improved their
clinical conditions over the 48-week period. 

These results are encouraging, particularly given the high unmet need for effective Parkinson’s
disease treatments. Current therapies primarily manage symptoms and often lose
efficacy over time. ANAVEX®2-73 could represent a new frontier in disease-modifying
treatments for Parkinson’s disease. 

Anavex, a clinical-stage biopharmaceutical company, plans to proceed with a pivotal trial based
on these findings. The company’s therapeutic platform includes ANAVEX®2-73 for
Alzheimer’s disease and Rett syndrome, alongside other CNS disorders. 

The study also noted a “drug holiday” period due to COVID-19, during which patients
experienced a decline in clinical scores. This phase provided a unique
opportunity to compare patient conditions with and without ANAVEX®2-73
treatment, further validating the drug’s effectiveness. 

Anavex Life Sciences continues to advance its research, driven by the
potential of ANAVEX®2-73 to address critical gaps in the treatment of
neurodegenerative diseases. The company remains committed to enhancing the
quality of life for patients through innovative therapeutic solutions. 

For more information, visit Anavex Life Sciences’ official website. 

Refer to this article for related information. 

Like their page on https://www.facebook.com/AnavexLifeSci/